The Human Microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult).
These microbes are generally not harmful to us, in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes.
An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease.
The global market for Human Microbiome was estimated to be worth US$ 384.9 million in 2023 and is forecast to a readjusted size of US$ 1544.9 million by 2030 with a CAGR of 21.7% during the forecast period 2024-2030.
At present, global investment concentrates in US and Europe, US takes 70% market share and Europe takes 25% market share. There are a few manufacturers in the world and the market concentration is high. The top5 (investment in Human Micobiome) companies are Vedanta, Seres Therapeutics, Second Genome, Rebiocix, ActoGeniX. The five companies occupy about 70% of the market share.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Human Microbiome, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyse their position in the current marketplace, and make informed business decisions regarding Human Microbiome.
The Human Microbiome market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Human Microbiome market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Human Microbiome companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
麻豆原创 Segmentation
By Company
Vedanta
Seres Therapeutics
Second Genome
Rebiotix
ActoGeniX
Enterome BioScience
AvidBiotics
4D Pharma Research Ltd
Enterologics
Metabogen
Metabiomics
Ritter Pharmaceuticals
Osel
Symberix
Miomics
Symbiotix Biotherapies
MicroBiome Therapeutics LLC
Segment by Type
Gastrointestinal Tract Human Micobiome
Urogenital Tract Human Micobiome
Others
Segment by Application
Treatment
Diagnosis
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on.
Chapter 2: Revenue of Human Microbiome in global and regional level.
Chapter 3: Detailed analysis of Human Microbiome company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Human Microbiome revenue, gross margin, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 8: Europe by Type, by Application and by country, revenue for each segment.
Chapter 9: Asia Pacific by Type, by Application and by region, revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Middle East and Africa, by Type, by Application and by country, revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Study Coverage
1.1 Human Microbiome Product Introduction
1.2 麻豆原创 by Type
1.2.1 Global Human Microbiome 麻豆原创 Size Growth Rate by Type (2019 VS 2023 VS 2030)
1.2.2 Gastrointestinal Tract Human Micobiome
1.2.3 Urogenital Tract Human Micobiome
1.2.4 Others
1.3 麻豆原创 by Application
1.3.1 Global Human Microbiome 麻豆原创 Size Growth Rate by Application (2019 VS 2023 VS 2030)
1.3.2 Treatment
1.3.3 Diagnosis
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Human Microbiome 麻豆原创 Size Estimates and Forecasts
2.2 Human Microbiome 麻豆原创 Size by Region: 2023 Versus 2030
2.2.1 Global Human Microbiome Revenue by Region: 2019-2024
2.2.2 Global Human Microbiome Revenue Forecast by Region (2025-2030)
2.2.3 Global Human Microbiome Revenue 麻豆原创 Share by Region (2019-2030)
3 Global Human Microbiome by Company
3.1 Global Human Microbiome Revenue by Company (2019-2024)
3.2 Global Human Microbiome Revenue Share by Company (2019-2024)
3.3 Competitive Landscape
3.3.1 Key Human Microbiome Companies around the World: Ranking by Revenue
3.3.2 Global Human Microbiome 麻豆原创 Concentration Ratio (CR5 and HHI) & (2019-2024)
3.3.3 Global Human Microbiome 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.4 Global Human Microbiome Companies Headquarters & Product Type
3.4.1 Human Microbiome Companies Headquarters
3.4.2 Global Human Microbiome Companies Product & Service
3.4.3 Date of International Companies Enter into Human Microbiome 麻豆原创
3.5 Global Human Microbiome Mergers & Acquisitions, Expansion Plans
4 Company Profiles
4.1 Vedanta
4.1.1 Vedanta Company Information
4.1.2 Vedanta Description, Business Overview
4.1.3 Vedanta Human Microbiome Products Offered
4.1.4 Vedanta Human Microbiome Revenue and Gross Margin (2019-2024)
4.1.5 Vedanta Human Microbiome Revenue by Product in 2023
4.1.6 Vedanta Human Microbiome Revenue by Application in 2023
4.1.7 Vedanta Human Microbiome Revenue by Geographic Area in 2023
4.1.8 Vedanta Recent Developments
4.2 Seres Therapeutics
4.2.1 Seres Therapeutics Company Information
4.2.2 Seres Therapeutics Description, Business Overview
4.2.3 Seres Therapeutics Human Microbiome Products Offered
4.2.4 Seres Therapeutics Human Microbiome Revenue and Gross Margin (2019-2024)
4.2.5 Seres Therapeutics Human Microbiome Revenue by Product in 2023
4.2.6 Seres Therapeutics Human Microbiome Revenue by Application in 2023
4.2.7 Seres Therapeutics Human Microbiome Revenue by Geographic Area in 2023
4.2.8 Seres Therapeutics Recent Developments
4.3 Second Genome
4.3.1 Second Genome Company Information
4.3.2 Second Genome Description, Business Overview
4.3.3 Second Genome Human Microbiome Products Offered
4.3.4 Second Genome Human Microbiome Revenue and Gross Margin (2019-2024)
4.3.5 Second Genome Human Microbiome Revenue by Product in 2023
4.3.6 Second Genome Human Microbiome Revenue by Application in 2023
4.3.7 Second Genome Human Microbiome Revenue by Geographic Area in 2023
4.3.8 Second Genome Recent Developments
4.4 Rebiotix
4.4.1 Rebiotix Company Information
4.4.2 Rebiotix Description, Business Overview
4.4.3 Rebiotix Human Microbiome Products Offered
4.4.4 Rebiotix Human Microbiome Revenue and Gross Margin (2019-2024)
4.4.5 Rebiotix Human Microbiome Revenue by Product in 2023
4.4.6 Rebiotix Human Microbiome Revenue by Application in 2023
4.4.7 Rebiotix Human Microbiome Revenue by Geographic Area in 2023
4.4.8 Rebiotix Recent Developments
4.5 ActoGeniX
4.5.1 ActoGeniX Company Information
4.5.2 ActoGeniX Description, Business Overview
4.5.3 ActoGeniX Human Microbiome Products Offered
4.5.4 ActoGeniX Human Microbiome Revenue and Gross Margin (2019-2024)
4.5.5 ActoGeniX Human Microbiome Revenue by Product in 2023
4.5.6 ActoGeniX Human Microbiome Revenue by Application in 2023
4.5.7 ActoGeniX Human Microbiome Revenue by Geographic Area in 2023
4.5.8 ActoGeniX Recent Developments
4.6 Enterome BioScience
4.6.1 Enterome BioScience Company Information
4.6.2 Enterome BioScience Description, Business Overview
4.6.3 Enterome BioScience Human Microbiome Products Offered
4.6.4 Enterome BioScience Human Microbiome Revenue and Gross Margin (2019-2024)
4.6.5 Enterome BioScience Human Microbiome Revenue by Product in 2023
4.6.6 Enterome BioScience Human Microbiome Revenue by Application in 2023
4.6.7 Enterome BioScience Human Microbiome Revenue by Geographic Area in 2023
4.6.8 Enterome BioScience Recent Development
4.7 AvidBiotics
4.7.1 AvidBiotics Company Information
4.7.2 AvidBiotics Description, Business Overview
4.7.3 AvidBiotics Human Microbiome Products Offered
4.7.4 AvidBiotics Human Microbiome Revenue and Gross Margin (2019-2024)
4.7.5 AvidBiotics Human Microbiome Revenue by Product in 2023
4.7.6 AvidBiotics Human Microbiome Revenue by Application in 2023
4.7.7 AvidBiotics Human Microbiome Revenue by Geographic Area in 2023
4.7.8 AvidBiotics Recent Development
4.8 4D Pharma Research Ltd
4.8.1 4D Pharma Research Ltd Company Information
4.8.2 4D Pharma Research Ltd Description, Business Overview
4.8.3 4D Pharma Research Ltd Human Microbiome Products Offered
4.8.4 4D Pharma Research Ltd Human Microbiome Revenue and Gross Margin (2019-2024)
4.8.5 4D Pharma Research Ltd Human Microbiome Revenue by Product in 2023
4.8.6 4D Pharma Research Ltd Human Microbiome Revenue by Application in 2023
4.8.7 4D Pharma Research Ltd Human Microbiome Revenue by Geographic Area in 2023
4.8.8 4D Pharma Research Ltd Recent Development
4.9 Enterologics
4.9.1 Enterologics Company Information
4.9.2 Enterologics Description, Business Overview
4.9.3 Enterologics Human Microbiome Products Offered
4.9.4 Enterologics Human Microbiome Revenue and Gross Margin (2019-2024)
4.9.5 Enterologics Human Microbiome Revenue by Product in 2023
4.9.6 Enterologics Human Microbiome Revenue by Application in 2023
4.9.7 Enterologics Human Microbiome Revenue by Geographic Area in 2023
4.9.8 Enterologics Recent Development
4.10 Metabogen
4.10.1 Metabogen Company Information
4.10.2 Metabogen Description, Business Overview
4.10.3 Metabogen Human Microbiome Products Offered
4.10.4 Metabogen Human Microbiome Revenue and Gross Margin (2019-2024)
4.10.5 Metabogen Human Microbiome Revenue by Product in 2023
4.10.6 Metabogen Human Microbiome Revenue by Application in 2023
4.10.7 Metabogen Human Microbiome Revenue by Geographic Area in 2023
4.10.8 Metabogen Recent Development
4.11 Metabiomics
4.11.1 Metabiomics Company Information
4.11.2 Metabiomics Description, Business Overview
4.11.3 Metabiomics Human Microbiome Products Offered
4.11.4 Metabiomics Human Microbiome Revenue and Gross Margin (2019-2024)
4.11.5 Metabiomics Human Microbiome Revenue by Product in 2023
4.11.6 Metabiomics Human Microbiome Revenue by Application in 2023
4.11.7 Metabiomics Human Microbiome Revenue by Geographic Area in 2023
4.11.8 Metabiomics Recent Development
4.12 Ritter Pharmaceuticals
4.12.1 Ritter Pharmaceuticals Company Information
4.12.2 Ritter Pharmaceuticals Description, Business Overview
4.12.3 Ritter Pharmaceuticals Human Microbiome Products Offered
4.12.4 Ritter Pharmaceuticals Human Microbiome Revenue and Gross Margin (2019-2024)
4.12.5 Ritter Pharmaceuticals Human Microbiome Revenue by Product in 2023
4.12.6 Ritter Pharmaceuticals Human Microbiome Revenue by Application in 2023
4.12.7 Ritter Pharmaceuticals Human Microbiome Revenue by Geographic Area in 2023
4.12.8 Ritter Pharmaceuticals Recent Development
4.13 Osel
4.13.1 Osel Company Information
4.13.2 Osel Description, Business Overview
4.13.3 Osel Human Microbiome Products Offered
4.13.4 Osel Human Microbiome Revenue and Gross Margin (2019-2024)
4.13.5 Osel Human Microbiome Revenue by Product in 2023
4.13.6 Osel Human Microbiome Revenue by Application in 2023
4.13.7 Osel Human Microbiome Revenue by Geographic Area in 2023
4.13.8 Osel Recent Development
4.14 Symberix
4.14.1 Symberix Company Information
4.14.2 Symberix Description, Business Overview
4.14.3 Symberix Human Microbiome Products Offered
4.14.4 Symberix Human Microbiome Revenue and Gross Margin (2019-2024)
4.14.5 Symberix Human Microbiome Revenue by Product in 2023
4.14.6 Symberix Human Microbiome Revenue by Application in 2023
4.14.7 Symberix Human Microbiome Revenue by Geographic Area in 2023
4.14.8 Symberix Recent Development
4.15 Miomics
4.15.1 Miomics Company Information
4.15.2 Miomics Description, Business Overview
4.15.3 Miomics Human Microbiome Products Offered
4.15.4 Miomics Human Microbiome Revenue and Gross Margin (2019-2024)
4.15.5 Miomics Human Microbiome Revenue by Product in 2023
4.15.6 Miomics Human Microbiome Revenue by Application in 2023
4.15.7 Miomics Human Microbiome Revenue by Geographic Area in 2023
4.15.8 Miomics Recent Development
4.16 Symbiotix Biotherapies
4.16.1 Symbiotix Biotherapies Company Information
4.16.2 Symbiotix Biotherapies Description, Business Overview
4.16.3 Symbiotix Biotherapies Human Microbiome Products Offered
4.16.4 Symbiotix Biotherapies Human Microbiome Revenue and Gross Margin (2019-2024)
4.16.5 Symbiotix Biotherapies Human Microbiome Revenue by Product in 2023
4.16.6 Symbiotix Biotherapies Human Microbiome Revenue by Application in 2023
4.16.7 Symbiotix Biotherapies Human Microbiome Revenue by Geographic Area in 2023
4.16.8 Symbiotix Biotherapies Recent Development
4.17 MicroBiome Therapeutics LLC
4.17.1 MicroBiome Therapeutics LLC Company Information
4.17.2 MicroBiome Therapeutics LLC Description, Business Overview
4.17.3 MicroBiome Therapeutics LLC Human Microbiome Products Offered
4.17.4 MicroBiome Therapeutics LLC Human Microbiome Revenue and Gross Margin (2019-2024)
4.17.5 MicroBiome Therapeutics LLC Human Microbiome Revenue by Product in 2023
4.17.6 MicroBiome Therapeutics LLC Human Microbiome Revenue by Application in 2023
4.17.7 MicroBiome Therapeutics LLC Human Microbiome Revenue by Geographic Area in 2023
4.17.8 MicroBiome Therapeutics LLC Recent Development
5 Breakdown Data by Type
5.1 Global Human Microbiome Revenue by Type (2019-2024)
5.2 Global Human Microbiome Revenue Forecast by Type (2025-2030)
5.3 Human Microbiome Revenue 麻豆原创 Share by Type (2019-2030)
6 Breakdown Data by Application
6.1 Global Human Microbiome Revenue by Application (2019-2024)
6.2 Global Human Microbiome Revenue Forecast by Application (2025-2030)
6.3 Human Microbiome Revenue 麻豆原创 Share by Application (2019-2030)
7 North America
7.1 North America Human Microbiome 麻豆原创 Size YoY Growth 2019-2030
7.2 North America Human Microbiome 麻豆原创 Facts & Figures by Country (2019-2030)
7.3 North America Human Microbiome Revenue by Type (2019-2024)
7.4 North America Human Microbiome Revenue by Application (2019-2024)
8 Asia-Pacific
8.1 Asia-Pacific Human Microbiome 麻豆原创 Size YoY Growth 2019-2030
8.2 Asia-Pacific Human Microbiome 麻豆原创 Facts & Figures by Region (2019-2030)
8.3 Asia-Pacific Human Microbiome Revenue by Type (2019-2024)
8.4 Asia-Pacific Human Microbiome Revenue by Application (2019-2024)
9 Europe
9.1 Europe Human Microbiome 麻豆原创 Size YoY Growth 2019-2030
9.2 Europe Human Microbiome 麻豆原创 Facts & Figures by Country (2019-2030)
9.3 Europe Human Microbiome Revenue by Type (2019-2024)
9.4 Europe Human Microbiome Revenue by Application (2019-2024)
10 Latin America
10.1 Latin America Human Microbiome 麻豆原创 Size YoY Growth 2019-2030
10.2 Latin America Human Microbiome 麻豆原创 Facts & Figures by Country (2019-2030)
10.3 Latin America Human Microbiome Revenue by Type (2019-2024)
10.4 Latin America Human Microbiome Revenue by Application (2019-2024)
11 Middle East and Africa
11.1 Middle East and Africa Human Microbiome 麻豆原创 Size YoY Growth 2019-2030
11.2 Middle East and Africa Human Microbiome 麻豆原创 Facts & Figures by Country (2019-2030)
11.3 Middle East and Africa Human Microbiome Revenue by Type (2019-2024)
11.4 Middle East and Africa Human Microbiome Revenue by Application (2019-2024)
12 Supply Chain and Sales Channel Analysis
12.1 Human Microbiome Supply Chain Analysis
12.2 Human Microbiome Key Raw Materials and Upstream Suppliers
12.3 Human Microbiome Clients Analysis
12.4 Human Microbiome Sales Channel and Sales Model Analysis
12.4.1 Human Microbiome Distribution Channel Analysis: Indirect Sales VS Direct Sales
12.4.2 Human Microbiome Distribution Channel Analysis: Online Sales VS Offline Sales
12.4.3 Human Microbiome Distributors
13 麻豆原创 Dynamics
13.1 Human Microbiome Industry Trends
13.2 Human Microbiome 麻豆原创 Drivers
13.3 Human Microbiome 麻豆原创 Challenges
13.4 Human Microbiome 麻豆原创 Restraints
14 Research Findings and Conclusion
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
Vedanta
Seres Therapeutics
Second Genome
Rebiotix
ActoGeniX
Enterome BioScience
AvidBiotics
4D Pharma Research Ltd
Enterologics
Metabogen
Metabiomics
Ritter Pharmaceuticals
Osel
Symberix
Miomics
Symbiotix Biotherapies
MicroBiome Therapeutics LLC
听
听
*If Applicable.
